Shares of Immunomedics, Inc. (NASDAQ:IMMU) are now up 100% year-to-date, and have risen particularly fast since the company significantly strengthened its balance sheet through both dilutive and non-dilutive financing measures earlier this year. Surprisingly, however, the company has garnered little attention from the media until recently. As a result, this precipitous move to the upside has gone largely unnoticed by the broader community of biotech investors and analysts. Indeed, Immunomedics's diverse pipeline, consisting of three late-stage and three-early stage clinical candidates, is likely partly to blame, as the pipeline's sheer complexity makes the company difficult to understand from both a valuation and operational viewpoint. Even so, I believe the company's two leading late-stage clinical candidates, clivatuzumab...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|